Are COVID Shots Fueling More Dangerous Mutations?

By Dr. Joseph Mercola | mercola.com

Story at-a-glance

  • When vaccines that don’t provide robust immunity are overused, they allow viruses to mutate in potentially hazardous ways. COVID variants with measurably different behavior emerged in mid-December 2020, which coincides with the rollout of the first COVID shots
  • While variants were identified in various areas before the shots were introduced in those same regions, vaccine makers were conducting large-scale trials on thousands of people in those areas well before the shots became available to the public, and before variants were detected
  • The COVID shots do not prevent infection or transmission, hence the variants created inside vaccinated individuals will spread. This hypothesis was confirmed in a 2015 study, which found that “imperfect vaccination can enhance the transmission of highly virulent pathogens”
  • Research shows fully vaccinated individuals who develop breakthrough infections with the Delta variant have the same viral loads as unvaccinated individuals infected with this virus, hence both groups can spread the infection to the same degree
  • Data from the U.S. Centers for Disease Control and Prevention show 74% of COVID-19 diagnoses in Barnstable County, Massachusetts, between July 6 through July 25, 2021, and 80% of hospitalizations, were among the fully vaccinated

Will mass injections against COVID-19 encourage the mutation of more dangerous versions of SARS-CoV-2? In the video above, WhatsHerFace questions why the U.K. government is procuring 6 million pounds worth of body bags, or “temporary body storage,” even as government officials announce that the current vaccination rate has “created a protective wall” against the infection.1

If that’s true, why are they expecting an “excess death scenario” requiring massive numbers of body bags? The procurement agreement will remain in effect for a period of four years. Does the U.K. government know something they’re not sharing with the public?

Have they peeked at the actual science and realized that mass vaccination during an active pandemic might encourage mutations that evade vaccine-induced defenses, or that the gene-modifying injections might render the vaccinated more susceptible to serious illness and death through a mechanism known as antibody-dependent enhancement (ADE) or the more descriptive term, paradoxical immune enhancement (PIE)?

Where Are the Variants Coming From, and Why Now?

WhatsHerFace highlights some of the answers given by health professionals on social media when asked why no problematic variants emerged during the first year when no COVID injections were available, and only popped up after the mass injection campaign started.

According to one such answer, “Our surveillance sucked in the beginning and it takes time for variants to come about but once they come they become rampant.” Interestingly, as noted in a February 15, 2021, article in The Conversation,2 variants with “measurably different behavior” did not emerge until mid-December 2020, which just so happens to be the exact time at which the first COVID shots were rolled out.

Fact-checkers have tried to debunk any connection between COVID shot rollouts and the emergence of variants by showing that variants were identified in various areas before the shots were introduced in those same regions. However, as noted by WhatsHerFace, vaccine makers were conducting large-scale trials in those areas well before the shots became available to the public.

For example, Pfizer enrolled more than 46,000 participants in the U.S., Argentina, Brazil, South Africa, Germany, and Turkey,3 and Oxford/AstraZeneca injected 23,000 participants in the U.K., Brazil, and South Africa.

“Now this is very interesting,” WhatsHerFace says, “because you’ll actually find that each of the areas where variants first emerged just happen to be the same countries where the trials took place.”

The Backstory of the Delta Variant

The Delta variant (B.1.617.2) was initially identified in India on December 1 and 11, 2020. While the COVID jabs were not rolled out in India until mid-January 2021, Phase 3 trials for Biotech’s Covaxin were initiated in Bharat, India, on November 16, 2020. By December 22, 2020, 22,500 volunteers had received the jab.

On a side note, the Indian government released Covaxin to the public before Phase 3 trials were completed and in the absence of any safety or efficacy data. According to some vaccinologists, the emergence of potentially more problematic variants following mass vaccination rollouts during an active pandemic is precisely what you’d expect.

Dr. Geert Vanden Bosche,4 whose resume includes work with GSK Biologicals, Novartis Vaccines, Solvay Biologicals, and the Bill & Melinda Gates Foundation, published an open letter5 to the World Health Organization, March 6, 2021.

In the letter, Bosche warned that implementing a global mass vaccination campaign during the height of the pandemic could create an “uncontrollable monster” where evolutionary pressure will force the emergence of new and potentially more dangerous mutations.

“There can be no doubt that continued mass vaccination campaigns will enable new, more infectious viral variants to become increasingly dominant and ultimately result in a dramatic incline in new cases despite enhanced vaccine coverage rates. There can be no doubt either that this situation will soon lead to complete resistance of circulating variants to the current vaccines,” Bossche wrote.6

‘Leaky’ Vaccines Promote Mutations

In short, when vaccines that don’t provide robust immunity are overused, they allow viruses to mutate in potentially hazardous ways. When you overuse an antibiotic that fails to eradicate the bacteria, antibiotic-resistant bacteria are allowed to flourish.

In the same way, overuse of a vaccine that doesn’t provide immunity can allow the virus to mutate inside vaccinated individuals into variants that evade vaccine-induced immunity.

And, as we already know, the COVID shots do not prevent infection or transmission, hence the variants created inside vaccinated individuals will spread, attacking both vaccinated and unvaccinated alike. This hypothesis was confirmed in a 2015 study7 in PLOS Biology, which found that “imperfect vaccination can enhance the transmission of highly virulent pathogens.” As explained by the authors:8

“There is a theoretical expectation that some types of vaccines could prompt the evolution of more virulent (‘hotter’) pathogens. This idea follows from the notion that natural selection removes pathogen strains that are so ‘hot’ that they kill their hosts and, therefore, themselves.

Vaccines that let the hosts survive but do not prevent the spread of the pathogen relax this selection, allowing the evolution of hotter pathogens to occur. This type of vaccine is often called a leaky vaccine. When vaccines prevent transmission, as is the case for nearly all vaccines used in humans, this type of evolution towards increased virulence is blocked.

But when vaccines leak, allowing at least some pathogen transmission, they could create the ecological conditions that would allow hot strains to emerge and persist.

This theory proved highly controversial when it was first proposed over a decade ago, but here we report experiments with Marek’s disease virus in poultry that show that modern commercial leaky vaccines can have precisely this effect: they allow the onward transmission of strains otherwise too lethal to persist.

Thus, the use of leaky vaccines can facilitate the evolution of pathogen strains that put unvaccinated hosts at greater risk of severe disease.”

This research was reported in a number of mainstream media publications, including Live Science,9 Newsweek10, and National Geographic.11 Quanta Magazine also took a deep dive into it in May 2018, closing the article with the following observation:12

“… the most crucial need right now is for vaccine scientists to recognize the relevance of evolutionary biology to their field. Last month, when more than 1,000 vaccine scientists gathered in Washington, D.C., at the World Vaccine Congress, the issue of vaccine-induced evolution was not the focus of any scientific sessions.

Part of the problem, [disease ecologist Andrew] Read says, is that researchers are afraid: They’re nervous to talk about and call attention to potential evolutionary effects because they fear that doing so might fuel more fear and distrust of vaccines by the public …”

The COVID shots, which do not make you immune against the virus but rather only lessen symptoms of infection, are a perfect example of leaky vaccines that can allow the virus to mutate within the mildly ill host, who then transmits the mutated virus to others. In this way, the shots can fuel a never-ending chain of outbreaks.

NPR Highlights How Vaccines Drive Viral Evolution

In a February 9, 2021, article,13 NPR highlighted this risk, stating that “vaccines could drive the evolution of more COVID-19 mutants.” According to NPR science correspondent Richard Harris, “the virus is always mutating. And if one happens to produce a mutation that makes it less vulnerable to the vaccine, that virus could simply multiply in a vaccinated individual.”

Simply having a virus mutating inside you isn’t necessarily dangerous, however. The viral load also plays an important role in determining how potentially dangerous a vaccinated individual who carries a mutation might be. If your viral load is low, the risk of you transmitting the mutated virus to others is also low. If your viral load is high, then the risk of transmission increases accordingly.

When it comes to the Delta variant, there’s bad news for those who have received one or more COVID shots, as research14 shows fully vaccinated individuals who develop breakthrough infections with the Delta variant have the same viral loads as unvaccinated individuals who are infected with this virus. As reported by Reuters on August 2, 2021:15

“Among people infected by the Delta variant of the coronavirus, fully vaccinated people with ‘breakthrough’ infections may be just as likely as unvaccinated people to spread the virus to others, new research suggests. The higher the amount of coronavirus in the nose and throat, the more likely the patient will infect others.

In one Wisconsin county, after Delta became predominant, researchers analyzed16 viral loads on nose-and-throat swab samples obtained when patients were first diagnosed. They found similar viral loads in vaccinated and unvaccinated patients, with levels often high enough to allow shedding of infectious virus.

‘A key assumption’ underlying current regulations aimed at slowing COVID-19 transmission ‘is that those who are vaccinated are at very low risk of spreading the virus to others,’ said study coauthor Katarina Grande of Public Health Madison & Dane County in Madison, Wisconsin.

The findings, however, indicate ‘that vaccinated people should take steps to prevent the spread of the COVID-19 virus to others,’ she added.”

Lambda Variant Shows Signs of Vaccine Resistance

The latest coronavirus on the block is Lambda, which was first identified in Peru. It’s now spreading through South America. Like the Delta variant, Lambda is more infectious than the original SARS-CoV-2 virus. Unlike Delta, it appears more resistant to vaccine-induced antibodies.

According to Reuters,17 three spike protein mutations “help it resist neutralization by vaccine-induced antibodies.” While some claim the emergence of Delta and Lambda is justification for a third booster shot, Rockefeller University researchers point out that a third dose might raise the number of antibodies, but it won’t improve their ability to neutralize viruses.18,19

If a third dose can’t neutralize any of the variants any better than two doses, then we’re back at the beginning of this vicious cycle where imperfect neutralization drives additional mutation.

The Rockefeller University paper also highlights the superior protection offered by natural immunity, which is what you get after you’ve recovered from an infection. According to the authors, “memory antibodies selected over time by the natural infection have greater potency and breadth than antibodies elicited by vaccination.”

For transparency, one of the coauthors, Michel Nussenzweig, told Reuters that if an updated injection capable of protecting against one or more specific variants were to become available, “then that would be the choice.”

I mention that, because the competing interest statement on that paper reveals the Rockefeller University “has filed a provisional patent application in connection with this work … (US patent 63/021,387). The patent has been licensed by Rockefeller University to Bristol Meyers Squib.”

An identical competing interest statement can also be found on other recent papers, including a preprint paper20 titled “Development of Potency, Breadth and Resilience to Viral Escape Mutations in SARS-CoV-2 Neutralizing Antibodies.”

At the time of writing, I got nothing but error messages when trying to access the U.S. patent office to confirm what U.S. patent 63/021,387 might be, but based on the papers bearing this competing interest statement, it sounds like the Rockefeller University might be patenting a new COVID shot against variants.

First COVID Shots Appear Ineffective Against Newer Variants

At the same time that Moderna and Pfizer raise prices on their individual COVID shots by 10% and 25% respectively,21 evidence of their ineffectiveness continues to mount.

In a July 30, 2021, report,22 Sharyl Attkisson cited data23 from the U.S. Centers for Disease Control and Prevention, which show that 74% of COVID-19 diagnoses in Barnstable County, Massachusetts, between July 6 through July 25, 2021, and 80% of hospitalizations, were among the fully vaccinated.

“The report contradicts multiple false reports that have claimed the vaccines are ‘100% effective’ in preventing hospitalization,” Attkisson writes.24

“It also contradicts false reports that have implied vaccinated people are not spreading Covid-19. According to CDC, the fully vaccinated are showing just as high of a ‘viral load’ as unvaccinated people who get infected.

CDC published new data25 on the topic in its weekly report. It says that most of the identified cases of Covid-19 in a Barnstable County, Massachusetts, town, in July (74%) were among fully vaccinated people.

Most, but not all, had the Delta variant. Additionally, four of five hospitalized patients were fully vaccinated. Only one was not fully vaccinated. Today, CDC also acknowledged that Covid-19 viral load is ‘similarly high’ in both vaccinated and unvaccinated people. That’s a result, say officials, of the Delta variant.

From the start, virologists said that there would be natural variants to Covid-19. They also accurately predicted that effectiveness of Covid-19 vaccines would wear down in a matter of months, not years. Now, CDC is confirming that the current Covid-19 vaccines are not working effectively against Covid-19.

In contrast, the millions of Americans who have fought off Covid-19 infections, either with or without symptoms, are proving to have greater and longer lasting immunity, so far, than those who have been vaccinated. That, too, was predicted by virologists.”

Americans are now told the Delta variant is a pandemic among the unvaccinated, even though the data doesn’t support this claim. The CDC appears to be trying to prop up this narrative by not reporting breakthrough infections in vaccinated individuals unless they are hospitalized or die.

Even then, they acknowledge them only if they have a positive PCR test run at a cycle threshold (CT) below 28,26 whereas unvaccinated people are still tested at a CT of 40 or above. The higher the CT, the greater the chance of a false positive.

Israeli Data Show Waning Effectiveness of Pfizer Shot

Israel is now recommending a third booster shot for people over the age of 60, as data27 shows the Pfizer injection is only 39% effective (relative risk reduction) against the Delta variant, down from 64% relative effectiveness two weeks earlier.

As of August 2, 2021, 66.9% of Israelis had received at least one dose of Pfizer’s injection; 62.2% had received two doses.28 A day earlier, August 1, the director of Israel’s Public Health Services, Dr. Sharon Alroy-Preis, announced half of all COVID-19 infections were among the fully vaccinated.29 Signs of more serious disease among fully vaccinated are also emerging, she said, particularly in those over the age of 60.

Alternative Treatments

In closing, remember there are several different treatment protocols for COVID-19 that appear just as effective for variants as for the original virus, including the following:

Sources and References

Pfizer to Seek Emergency Use Authorization for COVID Booster Shots — But CDC, FDA Say Science Is Lacking

By Megan Redshaw | The Defender

Pfizer announced Thursday it will seek Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in August for the third dose of its COVID-19 vaccine. The drugmaker predicted those who have been fully vaccinated will need a booster shot within six to 12 months of receiving their second dose of the Pfizer vaccine.

But hours later, the U.S. Department of Health and Human Services (HHS) issued a joint statement by the FDA and Centers for Disease and Control and Prevention (CDC) saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”

The statement did not explicitly mention Pfizer but said: “a science-based, rigorous process” headed by the CDC, FDA and the National Institutes of Health would determine when or whether boosters were necessary.

According to the HHS statement:

“FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data — which can include data from specific pharmaceutical companies, but does not rely on those data exclusively.”

In a statement to CNN Friday, the World Health Organization said:

“We don’t know whether booster vaccines will be needed to maintain protection against COVID-19 until additional data is collected,” adding, “limited data [is] available on how long the protection from current doses lasts, and whether an additional booster dose would be beneficial and for whom.”

Scientists “applauded the statement” from HHS, The Washington Post reported, saying boosters were not imminent and the science isn’t clear on if or when they will be needed.

“My opinion right now … is that current vaccination seems to be large‘ holding,’” said E. John Wherry, an immunologist at the University of Pennsylvania’s Perelman School of Medicine. “But the companies seem to suggest their continued follow-up of their trial patients shows concerning levels of the waning of immunity. Not much of these data from the companies are publicly available yet. I agree we need as much independent data and assessment as possible on this topic.”

John P. Moore, professor of microbiology and immunology at Weill Cornell Medicine, said:

“No one is saying we’ll never need a booster, but to say we need it now and give the public the impression the vaccines are failing and something needs to be done as a matter of urgency. … The time isn’t now. The decisions that are going to be made will be made by federal agencies.”

The HHS statement followed recommendations made June 23 by the CDC’s Advisory Committee on Immunization and Practices (ACIP). Members of the ACIP COVID-19 working group said they would recommend booster shots only if there were a demonstrated decline in efficacy — not just a waning antibody response.

Boosters may be recommended if there’s a variant that’s able to evade the vaccines, according to slides presented by Dr. Sara Oliver, a medical epidemiologist with the CDC’s National Center for Immunization and Respiratory Diseases.

Dr. Sharon Frey, ACIP member and clinical director of the Center for Vaccine Development at Saint Louis University Medical School, said:

“I would have to agree with the interpretation of the working group in the sense that there’s no data to support recommendations to support boosters at this time. There’s no evidence against declining protection at this time.”

Pfizer CEO insists boosters are needed

Pfizer has been working on two different booster strategies it anticipates could carry sales beyond the immediate pandemic need: a third 30 mg dose of its current vaccines and an updated vaccine that targets the South African variant.

All U.S. pharmaceutical companies involved in making COVID vaccines are working on formulating and testing booster shots to prepare for the possibility, The Washington Post reported.

Pfizer argued that as antibody blood concentration wanes, boosters will be required to ensure the broad population can’t carry the virus. This would quench the epidemic faster, the company said.

Pfizer said its vaccine’s effectiveness had eroded, citing two lines of evidence outside scientists have not seen in detail. This included an Israeli government analysis that showed reduced efficacy with Pfizer’s vaccine and the Delta variant and data from Pfizer’s continued follow-up of people who were vaccinated last summer.

“While protection against severe disease remained high across the full six months, the observed decline in efficacy against symptomatic disease over time, and the continued emergence of variants, are key factors driving our belief that a booster dose will likely be necessary to maintain highest levels of protection,” Pfizer said in a statement.

Pfizer said it would submit data to regulators within weeks showing the third dose of its vaccine at six months caused antibody levels to shoot up to five to 10 times higher than the original two-dose regimen. Moderna announced similar data in May.

Pfizer motivated by profit margins

Less than 24 hours after Pfizer announced plans to seek emergency use authorization of a third dose, the drugmaker’s stock was up 1.6%.

Pfizer CEO Albert Bourla has said for months a booster would likely be needed within a year of the initial two-dose inoculation — followed by annual vaccinations, even as public health officials and academic scientists said it wasn’t clear yet when a booster would be needed.

Booster shots for COVID are expected to serve as a key revenue driver in the years to come for Pfizer and its primary rival in the U.S., Moderna. Pfizer in May projected global sales of its COVID vaccine to reach $26 billion in 2021.

The company has also been frank that it’s current pricing — $19.50 per dose in the U.S. — is temporary. On an earnings call in February, Frank A. D’Amelio, Pfizer’s executive vice president of global supply, assured investors the company sees the vaccine market evolving as the pandemic wanes, and will likely be able to charge more per dose than it was getting under pandemic supply deals.

D’Amelio said a more typical price for vaccination was $150 or $175 per dose.

“Now, let’s go beyond a pandemic-pricing environment, the environment we’re currently in. Obviously, we’re going to get more on price,” D’Amelio said. “So clearly, there’s a significant opportunity for those margins to improve once we get beyond the pandemic environment that we’re in.”

Pfizer said it would begin testing a booster shot specifically programmed to combat the Delta variant in August, reaffirming concerns by scientists who predicted in April that pharmaceutical companies like Pfizer, would create a vaccine treadmill with continuous booster shots targeted at emerging variants.

CDC Experts Disagree With Pfizer on COVID Boosters, Threatening Pharma Giant’s Billion Dollar Revenue Stream

By Megan Redshaw | The Defender

As Pfizer makes plans to keep its billion-dollar revenue stream going — by assuring investors yearly COVID booster doses will be needed long after the pandemic ends — a group of scientists from the Centers for Disease Control and Prevention (CDC) said there isn’t enough data to recommend COVID booster shots to the general population.

The COVID-19 working group of the CDC’s Advisory Committee on Immunization Practices (ACIP) said on June 23, they would only recommend booster shots if there’s a demonstrated decline in efficacy –– not just a waning antibody response.

Boosters may also be recommended if there’s a variant that’s able to evade the vaccines, according to slides presented by Sara Oliver, M.D., a medical epidemiologist with CDC’s National Center for Immunization and Respiratory Diseases.

Currently, there’s no evidence to suggest a booster is needed, the experts said. Boosters may be appropriate for special risk groups in the future, including elderly people and transplant recipients. To be sure, the nation’s top public health officials said they would continue to monitor the situation.

“I would have to agree with the interpretation of the working group in the sense that there’s no data to support recommendations to support boosters at this time,” said Dr. Sharon Frey, member of the ACIP and clinical director of the Center for Vaccine Development at Saint Louis University Medical School. “There’s no evidence against declining protection at this time.”

Dr. Grace Lee, chair of the ACIP safety panel and professor of pediatrics at Stanford University School of Medicine, said she would like to see more evidence of breakthrough cases before recommending a booster shot.

“I would want greater certainty on the safety data if we’re talking about boosting before it’s clear what the risk data will look like,” Lee said. “If we’re seeing severe breakthrough cases then I think the decision-making moves forward even if there’s uncertainty with the safety data.”

CDC expert recommendations threaten Pfizer profits

Booster shots for COVID are expected to serve as a key revenue driver in the years to come for Pfizer and Moderna. Pfizer executives have assured investors the company sees the vaccine market evolving as the pandemic wanes, and will likely be able to charge more per dose than it was getting under pandemic supply deals.

Pfizer has been working on two different booster strategies it anticipates could carry sales beyond the immediate pandemic need — a third 30 mg dose of its current vaccines and an updated vaccine that targets the South African variant, Fierce Pharma reported.

No one is completely sure when a booster will be needed, but it’s possible that some of those who were vaccinated early on may need an extra jab as early as September, or roughly 8 to 12 months after their initial regimen, CEO Albert Bourla told Axios in May.

Pfizer has argued that boosters would be required “as antibody blood concentration wanes to ensure the broad population can’t carry the virus and thus quench the epidemic faster,” the Bernstein analysts, led by Ronny Gal, wrote to clients. That’s not the industry’s standard, and it’s also not what the CDC’s ACIP suggested at its meeting on June 23, analysts wrote.

A Pfizer spokesperson told Fierce Pharma the company’s “current thinking is that until we see a reduction in SARS-CoV-2 circulation and COVID-19 disease, we think it is possible that a third dose, a boost of our vaccine, could be needed to help provide protection against COVID-19,” subject to regulatory approval.

Pfizer’s COVID vaccine is already the second-highest revenue-generating drug in the world, with a projected revenue forecast of $26 billion in 2021 alone — a 70% increase in its originally projected profits.

The forecast is based on contracts to deliver 1.6 billion vaccine doses this year. The company expects to sign more deals for this year and is in supply talks with several countries for 2022 and beyond.

During an investor conference in March, Pfizer’s CFO Frank D’Amelio said the company sees “significant opportunity” for its COVID vaccine once the market shifts from a “pandemic situation to an endemic situation.”

At that point “factors like efficacy, booster ability, the clinical utility will basically become very important, and we view that as, quite frankly, a significant opportunity for our vaccine from a demand perspective, from a pricing perspective, given the clinical profile of our vaccine,” D’Amelio told the analyst.

During the Barclays’ Global Health Conference in March, D’Amelio said the company doesn’t see this as a one-time event, but “as something that’s going to continue for the foreseeable future.”

Bourla said a third dose of the company’s COVID vaccine was “likely” to be needed within a year of the initial two-dose inoculation — followed by annual vaccinations.

“Every year, you need to go to get your flu vaccine,” Bourla said. “It’s going to be the same with COVID. In a year, you will have to go and get your annual shot for COVID to be protected.”

Like Pfizer, Moderna’s chief commercial officer, Corinne M. Le Goff said during a call with investors in April that Americans could start getting booster shots of its vaccine later this year to protect against COVID variants.

“It is likely that the countries that have already achieved high vaccine coverage are going to be ready to shift their focus to boosters in 2022, and possibly even starting at the end of this year,” Le Goff said.

Johnson & Johnson (J&J) has said its vaccine will probably need to be given annually, despite being heavily marketed to consumers as a one-dose vaccine.

As The Defender reported in May, pharmaceutical companies and their CEOs have made billions from COVID vaccines, massive compensation packages, and questionable stock sales while reassuring investors that plans were underway for boosters and annual shots.

Big Pharma Already Developing COVID 2.0 Vaccines For New ‘Mutant’ Strain

The vaccine industry is already hard at work concocting the next wave of Wuhan coronavirus (COVID-19) vaccines, which will purportedly be used to fight a new “mutant” strain of the virus that officials claim is circulating in the United Kingdom.

British drug giant AstraZeneca will soon release a jab that chief executive Pascal Soriot says is fully capable of warding off the newest strain of the China Virus. Calling it a “winning formula,” Soriot says the injection will be just as effective as those offered by rivals like Pfizer and Moderna.

As soon as this week, U.K. authorities are expected to approve the AstraZeneca shot, which was developed in partnership with scientists from the University of Oxford. The jab is supposedly 70 percent effective, though the true figure is only about 62 percent when considering the “dosing error” that occurred during clinical trials.

“We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” Soriot told the media, insisting that AstraZeneca’s WuFlu vaccine is just as effective as the rival vaccines from Pfizer and Moderna.

“I can’t tell you more because we will publish at some point,” he added mysteriously as an almost gimmick.

More than 600,000 people were already vaccinated with Pfizer’s jab before Christmas

By as soon as the first week of January, Brits could be getting shot up with chemical blends that AstraZeneca says will keep them protected against infection with the novel coronavirus, including the newest strain that is supposedly making the rounds.

“So far, we think the vaccine should remain effective,” Soriot believes. “But we can’t be sure, so we’re going to test that.”

This newest strain is said to be far more infectious than earlier strains, though this does not mean that it is more harmful. Still, AstraZeneca wants people to get jabbed for it, and millions of them will likely obey.

The alleged rapid spread of this new disease variant prompted Prime Minister Boris Johnson to lock down the country just before the holidays, with threats of fine or arrest for those who attempted to travel in violation.

Nearly half of Great Britain, or around 24 million people, were told to stay home in isolation over the Christmas holiday, and many of these same folks will also be barred from doing anything fun for New Year’s.

All “non-essential” stores are now closed in these regions, as are restaurants and pubs. The only “essential” activity that is allowed is getting food for takeout – no indoor dining or socializing allowed, says Johnson.

While most of the attention has been on the U.K., other countries are also now claiming that this new “mutant” strain of the China Flu has spread within their borders as well.

As of Dec. 24, public health officials say that more than 600,000 people have already received the first of two doses of Pfizer’s Wuhan coronavirus (COVID-19) vaccine. Many are starting to get Moderna’s vaccine as well, this one having been approved not long after Pfizer’s and just in time for the holidays.

“How many ‘we think’ and ‘we can’t be sure’ does this article need to contain before anyone with common sense would reject this outright?” asked one Headline USA commenter about Soriot’s repeated use of uncertain verbiage to describe the alleged effectiveness of the AstraZeneca vaccine.

“Any of these vaccines supposedly have an effective rate of 95 percent for a virus that has its own cure rate of 99.6 percent. Hmmm … what to do, what to do?”

By Ethan A Huff | Science.News

Ethan Huff is a Staff Writer for Natural News and a freelance writer and health enthusiast who loves exploring the vast world of natural foods and health, digging deep to get to the truth. He runs an online health publication of his own at wholesomeherald.blogspot.com. He is also a staff writer for Naturalnews.com and a writer for Align Life.com.